Tag - makena

Provider Alert!
11Apr

Provider Alert! FDA Withdrawal of Makena®

Date: April 10, 2023 Attention: All Providers Effective Date: April 06, 2023 Call to action: Effective April 6, 2023, the U.S. Food and Drug Administration (FDA) announced the final decision to withdraw the approval of Makena and its generics, which was approved to reduce the risk of preterm birth in women pregnant with one baby who have a history of spontaneous preterm birth. Makena and its generics are no longer FDA approved and cannot be lawfully distributed. This is in result due to...

By Facilities, OB/GYNs, Office Managers, Primary Care Providers, Provider Alert, Specialists, , , , 0 CommentsRead more...
Provider Alert!
03Jun

Provider Alert! Revision to Makena Authorization Request Form 1345 Scheduled for June 10

Date: June 3, 2022 Attention: OB-GYN Providers Effective Date: June 10, 2022 Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event.  TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event. Call to action:  On June 10, 2022, Health and Human Services Commission (HHSC) will revise the Makena (hydroxyprogesterone caproate injection) authorization request form because the brand name Makena 250...

By OB/GYNs, Provider Alert, , 0 CommentsRead more...
Provider Alert!
29Jan

Provider Alert! URGENT – Makena (hydroxyprogesterone caproate) formulary change

Attention: OB providers Subject: URGENT - Makena (hydroxyprogesterone caproate) formulary change Effective Date: January 30, 2020   Call to action: The Texas Vendor Drug Program (VDP) will implement changes to the state Medicaid drug formulary, effective Thursday, January 30, 2020. Brand Makena formulations (intramuscular solution for injection, and subcutaneous auto-injectors) will remain on the preferred drug list (PDL). VDP has moved all generic hydroxyprogesterone caproate formulations to non-preferred drug status. Compounded formulations are not covered under the Medicaid formulary. Medicaid managed care plans are required...

By OB/GYNs, Provider Alert, , , , 0 CommentsRead more...